A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Sichuan Baili Pharmaceutical Co., Ltd.
Sichuan Baili Pharmaceutical Co., Ltd.
Imunon
CanariaBio Inc.
Merck Sharp & Dohme LLC
Daiichi Sankyo
National Cancer Center, Korea
National Cancer Center, Korea
AstraZeneca
AbbVie
pharmaand GmbH
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Women's Hospital School Of Medicine Zhejiang University
Shanghai Gynecologic Oncology Group
Ente Ospedaliero Ospedali Galliera
ImmunoGen, Inc.
Anhui Provincial Hospital
pharmaand GmbH
pharmaand GmbH
Vascular Biogenics Ltd. operating as VBL Therapeutics
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
AstraZeneca
West China Second University Hospital
Novartis
ImmunoGen, Inc.
Zhongnan Hospital
Shanghai Gynecologic Oncology Group
Zhongnan Hospital
Canadian Cancer Trials Group
Canadian Cancer Trials Group
GOG Foundation
Japanese Gynecologic Oncology Group
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Hospices Civils de Lyon
Peking Union Medical College Hospital
Japanese Gynecologic Oncology Group
National Cancer Institute (NCI)
GOG Foundation
Swiss Cancer Institute
Alliance for Clinical Trials in Oncology
Peking Union Medical College Hospital
Hospital General de Ciudad Real
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Amgen
OHSU Knight Cancer Institute
MEI Pharma, Inc.
AGO Study Group
AGO Study Group
Xian-Janssen Pharmaceutical Ltd.
SWOG Cancer Research Network